These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

247 related articles for article (PubMed ID: 21715361)

  • 21. Efficacy of erlotinib in patients with advanced non-small cell lung cancer: a pooled analysis of randomized trials.
    Gao H; Ding X; Wei D; Cheng P; Su X; Liu H; Aziz F; Wang D; Zhang T
    Anticancer Drugs; 2011 Oct; 22(9):842-52. PubMed ID: 21808188
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The effectiveness of erlotinib against brain metastases in non-small cell lung cancer patients.
    Bai H; Han B
    Am J Clin Oncol; 2013 Apr; 36(2):110-5. PubMed ID: 22391431
    [TBL] [Abstract][Full Text] [Related]  

  • 23. First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations.
    Sequist LV; Martins RG; Spigel D; Grunberg SM; Spira A; Jänne PA; Joshi VA; McCollum D; Evans TL; Muzikansky A; Kuhlmann GL; Han M; Goldberg JS; Settleman J; Iafrate AJ; Engelman JA; Haber DA; Johnson BE; Lynch TJ
    J Clin Oncol; 2008 May; 26(15):2442-9. PubMed ID: 18458038
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A phase I/II study of weekly high-dose erlotinib in previously treated patients with nonsmall cell lung cancer.
    Milton DT; Azzoli CG; Heelan RT; Venkatraman E; Gomez JE; Kris MG; Krug LM; Pao W; Rizvi NA; Dunne M; Miller VA
    Cancer; 2006 Sep; 107(5):1034-41. PubMed ID: 16878326
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Rationale for treatment and study design of tailor: a randomized phase III trial of second-line erlotinib versus docetaxel in the treatment of patients affected by advanced non-small-cell lung cancer with the absence of epidermal growth factor receptor mutations.
    Farina G; Longo F; Martelli O; Pavese I; Mancuso A; Moscetti L; Labianca R; Bertolini A; Cortesi E; Farris A; Fagnani D; Locatelli MC; Valmadre G; Ardizzoia A; Tomirotti M; Rulli E; Garassino MC; Scanni A
    Clin Lung Cancer; 2011 Mar; 12(2):138-41. PubMed ID: 21550561
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A phase II trial of erlotinib as front-line treatment in clinically selected patients with non-small-cell lung cancer.
    Pallis AG; Voutsina A; Kentepozidis N; Giassas S; Papakotoulas P; Agelaki S; Tryfonidis K; Kotsakis A; Vamvakas L; Vardakis N; Georgoulias V
    Clin Lung Cancer; 2012 Mar; 13(2):129-35. PubMed ID: 22000696
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Approval summary for erlotinib for treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of at least one prior chemotherapy regimen.
    Johnson JR; Cohen M; Sridhara R; Chen YF; Williams GM; Duan J; Gobburu J; Booth B; Benson K; Leighton J; Hsieh LS; Chidambaram N; Zimmerman P; Pazdur R
    Clin Cancer Res; 2005 Sep; 11(18):6414-21. PubMed ID: 16166415
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib.
    Eberhard DA; Johnson BE; Amler LC; Goddard AD; Heldens SL; Herbst RS; Ince WL; Jänne PA; Januario T; Johnson DH; Klein P; Miller VA; Ostland MA; Ramies DA; Sebisanovic D; Stinson JA; Zhang YR; Seshagiri S; Hillan KJ
    J Clin Oncol; 2005 Sep; 23(25):5900-9. PubMed ID: 16043828
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effects of erlotinib first-line maintenance therapy versus placebo on the health-related quality of life of patients with metastatic non-small-cell lung cancer.
    Juhász E; Kim JH; Klingelschmitt G; Walzer S
    Eur J Cancer; 2013 Apr; 49(6):1205-15. PubMed ID: 23477998
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Phase II clinical trial of chemotherapy-naive patients > or = 70 years of age treated with erlotinib for advanced non-small-cell lung cancer.
    Jackman DM; Yeap BY; Lindeman NI; Fidias P; Rabin MS; Temel J; Skarin AT; Meyerson M; Holmes AJ; Borras AM; Freidlin B; Ostler PA; Lucca J; Lynch TJ; Johnson BE; Jänne PA
    J Clin Oncol; 2007 Mar; 25(7):760-6. PubMed ID: 17228019
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Erlotinib: small-molecule targeted therapy in the treatment of non-small-cell lung cancer.
    Smith J
    Clin Ther; 2005 Oct; 27(10):1513-34. PubMed ID: 16330289
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Skin rash and bronchoalveolar histology correlates with clinical benefit in patients treated with gefitinib as a therapy for previously treated advanced or metastatic non-small cell lung cancer.
    Dudek AZ; Kmak KL; Koopmeiners J; Keshtgarpour M
    Lung Cancer; 2006 Jan; 51(1):89-96. PubMed ID: 16290256
    [TBL] [Abstract][Full Text] [Related]  

  • 33. An expanded access program of erlotinib (Tarceva) in patients with advanced non-small cell lung cancer (NSCLC): data report from Italy.
    Tiseo M; Gridelli C; Cascinu S; Crinò L; Piantedosi FV; Grossi F; Brandes AA; Labianca R; Siena S; Amoroso D; Belvedere O; Valentino B; Bearz A; Venturino P; Ardizzoni A
    Lung Cancer; 2009 May; 64(2):199-206. PubMed ID: 18951651
    [TBL] [Abstract][Full Text] [Related]  

  • 34. TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer.
    Herbst RS; Prager D; Hermann R; Fehrenbacher L; Johnson BE; Sandler A; Kris MG; Tran HT; Klein P; Li X; Ramies D; Johnson DH; Miller VA;
    J Clin Oncol; 2005 Sep; 23(25):5892-9. PubMed ID: 16043829
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Randomized phase II trial of erlotinib or standard chemotherapy in patients with advanced non-small-cell lung cancer and a performance status of 2.
    Lilenbaum R; Axelrod R; Thomas S; Dowlati A; Seigel L; Albert D; Witt K; Botkin D
    J Clin Oncol; 2008 Feb; 26(6):863-9. PubMed ID: 18281658
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Second-line erlotinib in patients with advanced non-small-cell lung cancer: subgroup analyses from the TRUST study.
    Heigener DF; Wu YL; van Zandwijk N; Mali P; Horwood K; Reck M
    Lung Cancer; 2011 Nov; 74(2):274-9. PubMed ID: 21439671
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Efficacy and toxicity of erlotinib in non-small cell lung cancer treatment].
    Romero-Ventosa EY; Mucientes-Molina A; Pedrido-Reino E; Lago-Rivero N; Constenla-Caramés L; Arias-Santos I
    Farm Hosp; 2012; 36(2):68-76. PubMed ID: 21798783
    [TBL] [Abstract][Full Text] [Related]  

  • 38. EGFR-tyrosine kinase inhibitor treatment beyond progression in long-term Caucasian responders to erlotinib in advanced non-small cell lung cancer: a case-control study of overall survival.
    Faehling M; Eckert R; Kamp T; Kuom S; Griese U; Sträter J; Ott G; Spengler W
    Lung Cancer; 2013 Jun; 80(3):306-12. PubMed ID: 23489557
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Erlotinib for pretreated squamous cell carcinoma of the lung in Japanese patients.
    Hata A; Katakami N; Kunimasa K; Yoshioka H; Fujita S; Kaji R; Tachikawa R; Tomii K; Imai Y; Iwasaku M; Ishida T
    Jpn J Clin Oncol; 2011 Dec; 41(12):1366-72. PubMed ID: 22058419
    [TBL] [Abstract][Full Text] [Related]  

  • 40. FDA drug approval summary: erlotinib (Tarceva) tablets.
    Cohen MH; Johnson JR; Chen YF; Sridhara R; Pazdur R
    Oncologist; 2005 Aug; 10(7):461-6. PubMed ID: 16079312
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.